INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Shares of Hims & Hers Health fell over 25% on June 23 after Novo Nordisk announced it was terminating its partnership with the company, citing “deceptive marketing” and “illegal mass compounding” of semaglutide-based weight-loss treatments. The collaboration between the two healthcare companies launched in April, and allowed Hims to offer Wegovy through its telehealth platform. According to Novo Nordisk, Hims continued selling compounded versions of semaglutide even after the FDA determined that Novo Nordisk's Wegovy was no longer in shortage.

To learn more about the Hims & Hers investigation, go to www.faruqilaw.com/HIMS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250623922129/en/